返回 Agenda
Update from CBER: Advancing the Development of Complex Biologic Products
Session Chair(s)
Peter W. Marks, MD, PHD
DIA Fellow, United States
This session will provide an overview of how the Center for Biologics Evaluation and Research (CBER) works to advance the development of complex biological products such as vaccines, live biotherapeutics, and cellular and gene therapies. The session will include a discussion of how the Center is working to implement relevant provision of the 21st Century Cure Act aimed at further expediting the development of important medical products.